Earticle

현재 위치 Home

Original Article

Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제32권 제3호 (2022.09)바로가기
  • 페이지
    pp.191-203
  • 저자
    Mi Seon Park, Young-Mo Yang, Ki Hyun Park, Hyonok Yoon, Ju Sin Kim, Eun Joo Choi
  • 언어
    영어(ENG)
  • URL
    https://www.earticle.net/Article/A418382

※ 기관로그인 시 무료 이용이 가능합니다.

4,500원

원문정보

초록

영어
Background: Direct-acting antivirals are recommended for the treatment of chronic hepatitis C virus in Korea. However, evaluation of direct-acting antiviral regimens in a real-world setting is limited. The aims of this study were to investigate the effectiveness and safety of direct-acting antiviral treatment in Korean patients infected with chronic hepatitis C virus genotype 1b or 2 at a tertiary care hospital. Methods: This was a retrospective study conducted with patient data obtained between August 2015 and August 2019 at Jeonbuk National University Hospital. The primary effectiveness endpoint was sustained virological response 12 weeks posttreatment (SVR12) via intention-to-treat (ITT) and modified intention-to-treat (mITT) analyses. Results: Of the 270 patients, 47.0% were infected with genotype 1b and 53.0% with genotype 2. ITT analysis revealed that SVR12 was achieved in 78.9% of all patients, 77.2% in genotype 1b patients, and 80.4% in genotype 2 patients. Of the 21.1% of all patients who did not achieve SVR12, the majority of treatment failures were non-virologic failures (19.7%). mITT analysis revealed that SVR12 was achieved in 98.2% of all patients, 98.0% in genotype 1b patients, and 98.3% in genotype 2 patients. Almost half of all patients experienced one or more adverse events (43.3%), leading to 2.6% discontinuing scheduled treatment. The most common adverse event was anemia. Conclusions: Direct-acting antiviral-based treatment regimens showed high effectiveness and safety. Non-virological factors, such as premature treatment discontinuation due to adverse events or loss of follow-up, were the major disruptors in achieving SVR12.

목차

ABSTRACT
Methods
Ethics
Patients and treatment
Measurements
Assessment and analysis
Statistical analyses
Results
Characteristics of patients
Use patterns of DAAs
Virological effectiveness (SVR12)
Biochemical responses
Safety assessment
Discussion
Conflicts of Interest
References

키워드

Direct-acting antiviral treatment effectiveness hepatitis C virus safety sustained virological response (SVR)

저자

  • Mi Seon Park [ Department of Pharmacy, College of Pharmacy, Chosun University, Department of Pharmacy, Jeonbuk National University Hospital ]
  • Young-Mo Yang [ Department of Pharmacy, College of Pharmacy, Chosun University ]
  • Ki Hyun Park [ Department of Pharmacy, College of Pharmacy, Chosun University ]
  • Hyonok Yoon [ Department of Pharmacy, Research Institute of Pharmaceutical Sciences, Gyeongsang National University ]
  • Ju Sin Kim [ Department of Pharmacy, Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea ]
  • Eun Joo Choi [ Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea ] Corresponding Author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제32권 제3호

    피인용수 : 0건 (자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      출처 : 네이버학술정보

        0개의 논문이 장바구니에 담겼습니다.

        페이지 저장
        소속기관 조회
        이용자님의 소속기관(단체)이 서비스에 가입되어 있는지 확인해 보십시오.
        기관회원에 소속되어 있는 이용자는 원문을 무료로 이용할 수 있습니다.